MaxCyte, Inc. Signing of Strategic Platform License (5279Y)
03 1월 2024 - 10:05PM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 5279Y
MaxCyte, Inc.
03 January 2024
MaxCyte and Lion TCR form Partnership to Support Global
Expansion of Lion TCR's
TCR-T Cell Pipeline
Lion TCR to use MaxCyte's Flow Electroporation(R) technology and
ExPERT(TM) platform to develop and scale TCR-T cell therapies for
solid tumors and viral-related diseases.
ROCKVILLE, MD, and SINGAPORE, January 3, 2024 - MaxCyte, Inc. ,
(Nasdaq: MXCT; LSE: MXCT), a leading, cell- engineering focused
company providing enabling platform technologies to advance the
discovery, development and commercialization of next-generation
cell therapeut ics and innovative bioprocessing applications , and
Lion TCR , an Asia -based, clinical-stage biotechnology company
focused on the development of T cell receptor ( TCR)-T cell
therapies for solid tumors and life-threatening viral infections
today announced the signing of a strategic platform license (SPL).
This partnership will enhance MaxCyte's presence in Asia, with
anticipated expansion into the US and European markets.
Under the terms of the agreement, Lion TCR obtains worldwide
non-exclusive clinical and commercial rights to use MaxCyte's Flow
Electroporation(R) technology and ExPERT(TM) platform. In return,
MaxCyte is entitled to receive annual license fees and
program-related revenue.
"We are thrilled to partner with Lion TCR to support the
development of their TCR-T cell therapies for hepatocellular
carcinoma and life-threatening viral infections," said Maher
Masoud, President and CEO of MaxCyte. "Through this important
partnership, we will be able to help provide the opportunity for
patients in Asia (and ultimately patients worldwide) to benefit
from these innovative mRNA-based TCR-T cell treatments and continue
supporting the development of new therapies for patients with solid
tumors."
Lion's proprietary TCR-T cell therapy platform is supported by
robust research, in collaboration with renowned laboratories, in
the areas of autologous T cells and 'off-the-shelf' technologies.
The company's TCR-T cell therapy harnesses the patient's own immune
system to fight against viral infections and cancers. The company
is con ducting ongoing clinical trials against hepatocellular
carcinoma to evaluate the safety and efficacy of its TCR-T cells.
Lion has engineered Hepatitis B virus (HBV)-specific T cells to
recognize HBV-expressing tumor cells and achieve targeted killing,
which is key as HBV is a major cause of hepatocellular
carcinoma.
"At Lion TCR, we aspire to be the world's leader in the field of
mRNA-based TCR-T therapeutics through the technological advancement
and development of adoptive T cell therapy products for cancers and
cancer-causing infectious diseases," said CEO, Xiaoming Peng PhD,
MBA. "We are honored to have MaxCyte as a partner and leverage
their large-scale flow electroporation technology to support our
development of novel therapeutics to benefit patients suffering
from these devastating diseases."
MaxCyte's ExPERT(TM) instrument portfolio is the next generation
of leading, clinically-validated electroporation technology for
complex and scalable cell engineering. By delivering high
transfection efficiency, seamless scalability and enhanced
functionality, the ExPERT(TM) platform delivers the high-end
performance essential to enabling the next wave of biological and
cellular therapeutics. Lion TCR is MaxCyte's 24th strategic
partnership overall, each of which generates pre-commercial
milestone revenue and the vast majority of which include
sales-based payments.
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize
the potential of cells to improve patients' lives. We have spent
more than 20 years honing our expertise by building best-in-class
platforms, perfecting the art of the transfection workflow, and
venturing beyond today's processes to innovate tomorrow's
solutions. Our ExPERT(TM) platform, which is based on our Flow
Electroporation (R) technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM), GTx(TM)
and VLx (TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology, as well as scientific,
technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more at maxcyte.com and
follow us on Twitter and LinkedIn .
About Lion TCR Pte Ltd
Lion TCR, a clinical stage biotech spun off from Singapore's
A*STAR, specializes in engineered T Cell Receptor (TCR) T cell
therapies for infectious diseases and associated cancers,
particularly HBV-related hepatocellular carcinoma (HCC). Lion TCR
have secured FDA IND approval for a Phase 1b/2 trial - the world's
first FDA-approved international multi-center trial for its HBV
TCR-T therapy (LioCyx-M004) against HCC. Additionally, LioCyx-M004
has received dual Fast Track and Orphan Drug Designations from the
FDA. Lion TCR's groundbreaking approach involves utilizing mRNA to
encode HBV-specific TCR in patients' T cells, enabling the
targeting of HBV epitopes expressed in liver cancer cells. Positive
clinical trial outcomes attest to its efficacy. Building on their
mRNA technology and AI-enabled TCR discovery platforms, Lion TCR
extends its focus to solid tumors, offering personalized cell
therapy and 'off-the-shelf' solutions. This positions Lion TCR to
develop a robust pipeline for diverse solid cancers and chronic
viral diseases. Learn more at liontcr.com .
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Seismic Collaborative
Valerie Enes
+1 408-497-8568
venes@spectrumscience.com
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
ICR Consilium
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
Lion TCR Contacts:
2 Tukang Innovation Grove
#09-04
Singapore 618305
+65 68130738
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBJMMTMTBMBLI
(END) Dow Jones Newswires
January 03, 2024 08:05 ET (13:05 GMT)
Maxcyte (LSE:MXCT)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Maxcyte (LSE:MXCT)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024